Replies to post #171489 on Biotech Values

[oc631]

No doubt about it—pricing in going to play a big role in how this market shakes out. Outside the US, this will be true to an even greater extent.

Do you have an opinion as to how GILD will handle GT1 Sofo/Ledi pricing? Will the combo be premium priced in relation to Sofo/Riba due to the NS5A inhibitor component? Or will they keep the 12-week combo at price parity with Sofo/Riba due to competitive pressure?